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A B S T R A C T
Purpose
The ideal duration of adjuvant chemotherapy for patients with lower risk primary breast cancer is
not known. Cancer and Leukemia Group B trial 40101 was conducted using a phase III factorial
design to define whether six cycles of a chemotherapy regimen are superior to four cycles. We
also sought to determine whether paclitaxel (T) is as efficacious as doxorubicin/cyclophosphamide
(AC), but with reduced toxicity.
Patients and Methods
Between 2002 and 2008, the study enrolled women with operable breast cancer and zero to
three positive nodes. Patients were randomly assigned to either four or six cycles of either AC
or T. Study stratifiers were estrogen receptor/progesterone receptor (ER/PgR), human
epidermal growth factor receptor 2 (HER2), and menopausal status. After 2003, all treatment
was administered in dose-dense fashion. The primary efficacy end point was relapse-free
survival (RFS).
Results
A total of 3,171 patients were enrolled; 94% were node-negative and 6% had one to three positive
nodes. At a median follow-up of 5.3 years, the 4-year RFS was 90.9% and 91.8% for six and four
cycles, respectively. The adjusted hazard ratio (HR) of six to four cycles regarding RFS was 1.03
(95% CI, 0.84 to 1.28; P  .77). The 4-year OS was 95.3% and 96.3% for six and four cycles,
respectively, with an HR of six to four cycles of 1.12 (95% CI, 0.84 to 1.49; P  .44). There was
no interaction between treatment duration and chemotherapy regimen, ER/PgR, or HER2 status
on RFS or OS.
Conclusion
For women with resected primary breast cancer and zero to three positive nodes, we found no
evidence that extending chemotherapy regimens of AC or single-agent T from four to six cycles
improves clinical outcome.
J Clin Oncol 30:4071-4076. © 2012 by American Society of Clinical Oncology
INTRODUCTION
The ideal duration of adjuvant therapy for women
with low-risk primary breast cancer is not known.
National Surgical Adjuvant Breast and Bowel Proj-
ect (NSABP) trial B-15 compared six cycles of cyclo-
phosphamide, methotrexate, and fluorouracil (FU;
CMF)withfourcyclesofdoxorubicinandcyclophos-
phamide (AC) and found them to be equivalent,
and subsequent clinical trials have used both of these
regimens as control arms.1 Four cycles of AC was the
basis for Cancer and Leukemia Group B (CALGB)
and NSABP trials that examined the potential bene-
fit of adding a taxane to the treatment.2,3 Six cycles of
CMF was the control arm of the study comparing six
cycles of cyclophosphamide, doxorubicin, and FU
(CAF) in women with node-negative breast cancer
by the North American Breast Intergroup and
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Southwest Oncology Group.4 More recently, four cycles of AC has
been the control arm when testing taxane-containing regimens, such
asdoxorubicin-docetaxelbyGoldsteinetal5 anddocetaxel-cyclophos-
phamide by Jones et al.6 Martin et al7 compared six cycles of CAF with
six cycles of docetaxel, doxorubicin, and FU for women with node-
negative breast cancer.
To address the question of treatment duration, the CALGB,
together with Eastern Cooperative Oncology Group, Southwest On-
cology Group, and North Central Cancer Treatment Group, initiated
a randomized, phase III, 2  2 factorial trial (CALGB 40101) designed
to assess the first factor (six cycles of therapy v four cycles of therapy)
and the second factor (single-agent T v AC). This article describes the
results of the comparison of six cycles versus four cycles of therapy.
PATIENTS AND METHODS
The trial was initiated in 2002 as a 2  2 factorial design comparing longer
versusshortertherapyandACversussingle-agentTinwomenwithnode-negative
disease. AC was administered once every 3 weeks for four (12 weeks) or six (18
weeks) cycles and T was administered weekly for 12 or 18 weeks (3 weeks of T was
considered one cycle). Five hundred seventy-one patients were accrued using this
trial design. In 2003, when the results of CALGB 9741 showed the superiority of
dose-densetherapyadministeredevery2weekscomparedwithevery3weeks,8our
trialwasamendedsothatbothACandTwereadministeredevery2weeks for four
or six cycles. AC was administered as doxorubicin 60 mg/m2 and cyclophospha-
mide as 600 mg/m2. Paclitaxel was administered as 80 mg/m2 when given weekly
and 175 mg/m2 when given every 2 weeks.
In 2005, women with one to three positive axillary nodes were permitted
onto the study. In February 2008, the six-cycle arms were closed to accrual with
3,171 patients enrolled onto the study. The study design then changed to a
two-arm study comparing four cycles of AC with four cycles of T. The study
was permanently closed to accrual in July 2010 owing to declining enrollment,
at which time 3,871 patients were enrolled.
Hormone therapy (tamoxifen for any patient or aromatase inhibitors in
postmenopausal women) was recommended for patients with hormone-re-
ceptor–positive tumors. After 2005, trastuzumab was recommended for women
with human epidermal growth factor receptor 2 (HER2) –positive tumors.
Women randomly assigned to receive AC were recommended to start trastu-
zumab after the conclusion of AC, and women randomly assigned to receive T
could initiate trastuzumab concurrently with T or after completion of T.
Radiation therapy was required for women undergoing breast-conserving
surgery, though the type of radiation (whole breast, partial breast, implant, and so
on)wasdeterminedbythetreatingphysicians.Postmastectomyradiationcouldbe
administered at the discretion of the treating physicians.
Patients must have been enrolled and received random assignment
within 84 days of their last breast surgery, and treatment had to be initiated
within 7 days of random assignment. Stratification factors included meno-
pausal status, hormone-receptor status, and HER2 status.
Primary objectives of the study were to test the superiority of six cycles of
therapy over four cycles of therapy and the equivalence of T compared with AC,
both in regard to relapse-free survival (RFS). Secondary objectives included the
same comparisons in regard to overall survival (OS). Other secondary objectives
includedtheevaluationoftoxicitiesforACversusTandsixcyclesversusfourcycles
of therapy and the induction of menopause in premenopausal women by treat-
ment arm. There were two companion studies designed to accompany the parent
study. One was a quality of life companion trial designed to study the impact of
short- and long-term toxicities on quality of life by treatment agent and duration.
The second study was a pharmacogenomic companion study designed to assess
whether germline polymorphisms would influence toxicity for AC or T and sur-
vival outcomes. Each patient gave written approval on a protocol-specific, institu-
tional review board–approved, consent form.
The primary study end point was RFS, defined according to standardized
efficacy end point criteria, measured from study entry until local recurrence,
distant relapse, or death without relapse, whichever occurred first.9 All second
cancer primaries, regardless of site, were considered adverse events and not
failures in RFS. Surviving patients who were relapse-free were censored at the
date they were last known to be free from their primary breast cancer. The
secondary end point of OS was measured from study entry until death from
any cause; surviving patients were censored at the date of last contact. Death as
a result of acute myeloid leukemia/myelodysplastic syndrome (AML/MDS)
was considered treatment-related.
The primary comparison of treatment length used proportional hazards
modeling that adjusted for tumor size, number of involved lymph nodes,
hormone receptor status (either estrogen-receptor [ER] or progesterone-





Excluded as a result of 
no informed consent
(n = 2)
Every 3 weeks (n = 140)
Every 2 weeks (n = 1,002)
Analyzed (n = 795)
Excluded* (n = 347)
  (ie, enrolled after AC × 6, 
   T × 6 arms closed)
Every 3 weeks (n = 144)
Every 2 weeks (n = 645)
Analyzed (n = 789)
Excluded* (n = 0)
Every 3 weeks (n = 146)
Every 2 weeks (n = 1,005)
Analyzed (n = 798)
Excluded* (n = 353)
  (ie, enrolled after AC × 6, 
   T × 6 arms closed)
Every 3 weeks (n = 141)
Every 2 weeks (n = 648)
Analyzed (n = 789)
Excluded* (n = 0)
Allocated to AC × 4
(n = 1,142)
Allocated to AC × 6
(n = 789)
Allocated to T × 4
(n = 1,151)
Allocated to T × 6
(n = 789)
Fig 1. CONSORT diagram showing patients registered, treatment arm assignments, and exclusions. AC, doxorubicin and cyclophosphamide; T, paclitaxel.
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status. The statistical significance of each variable included in the models was
assessed using the corresponding Wald 2 statistics. Hazard ratios (HR) and
their 95% CI were obtained from multivariate proportional hazards models.
RFS and OS distributions were estimated using the Kaplan-Meier product-
limit technique.10 Log-rank tests compared distributions of two or more
groups.11 95% CIs of time-to-event variables were measured using the Hos-
mer and Lemeshow method.12 Efficacy analyses used an intention-to-treat
approach. All adverse events were reported using National Cancer Institute
common toxicity criteria.13 P values are two-sided.
To test the superiority in RFS of six over four cycles of protocol therapy,
the study was powered against a two-sided (  .05) alternative hypothesis
with an HR of 0.77 corresponding to a decrease of 23% in hazard of relapse
attributed to six cycles. With a target accrual of 4,646 patients accrued over 29
months and four additional years of follow-up, there was 91% power to detect
the stated difference. Under the alternative hypothesis, the expected total
number of events was 567.
In accordance with National Cancer Institute policy, our study was
monitored every 6 months by an independent data and safety monitoring
board (DSMB) beginning in November 2002. Preplanned interim analyses to
stop study early for the superiority of six over four cycles used symmetric
O’Brien-Fleming bounds for a two-sided hypothesis and a Lan-DeMets
spending function. Early stopping for futility was not planned. The first formal
interim analysis, scheduled at 10% of the total expected events, was conducted
in June 2006. Thereafter, interim analyses were conducted every 6 months
until June 2008. In June 2010, the DSMB released the results for the four-
versus six-cycle comparison.
Study data were collected by CALGB Data Operations and stored in the
CALGB database. All analyses were conducted by CALGB statisticians. Data
were current as of August 2011.
RESULTS
Between study activation in May 2002 and closure of the six-cycle
arms in February 2008, a total of 3,171 patients were accrued. These
patients comprise the assessable sample in our article. In June 2010,
the DSMB released data for the six- versus four-cycle comparison.
Although no observed statistics crossed the interim superiority
boundaries, the Bayesian predictive probability for concluding supe-
riority of the six-cycle regimens over the four-cycle regimens was .001.
Specifically, based on observed available data, the probability of con-
cluding superiority if the trial had run to completion by achieving the
target accrual of 4,646 patients and expected 567 total events was only
.001. This probability assumed exponential survival with independent
and noninformative prior distributions about the parameters and was
based on 283 events and an observed HR of 6:4 cycles of 1.12 (95% CI,
0.89 to 1.42). The prediction assumed that the eventual conclusion
would have a two-sided of .05 as specified in the protocol.
Patient Characteristics
Patients enrolled, patients excluded from analysis and the
reasons for their exclusion, and the final numbers analyzed are
shown in Figure 1. The patient characteristics are well balanced
between study arms as listed in Table 1. Sixty-four percent of
patients had T1 tumors, 64% had ER-positive tumors, 23% had
tumors that were positive for HER2 overexpression or amplifica-
tion, 47% had high-grade tumors, and 94% of patients had node-
negative disease. Forty-four percent of patients in both groups
were premenopausal. At the time of reporting, 45 patients (1%)
were lost to follow-up, and 57 patients (2%) had withdrawn con-
sent to receive follow-up. The median follow-up period for surviv-
ing patients was 5.3 years, with a maximum of 8.9 years.
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4 cycles 1,593 1,465 1,081 491 43






















4 cycles 1,593 1,521 1,167 578 59
6 cycles 1,578 1,502 1,155 552 37





Fig 2. (A) Relapse-free and (B) overall survival comparing four cycles versus six cycles of therapy. HR, hazard ratio.









Age  50 years 59 59 59
Nonwhite 16 15 15
Premenopausal 44 44 44
Node-negative 94 93 94
Tumor size  2 cm 66 62 64
ER-positive tumors 65 64 64
HER2-negative
tumors 77 77 77
High grade 47 48 47
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor
receptor 2.
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Efficacy End Points
The 4-year RFS was 90.9% for patients randomly assigned to six
cycles of therapy and 91.8% for patients randomly assigned to four
cycles. The 4-year OS for patients randomly assigned to six cycles of
therapy was 95.3% and 96.3% for patients randomly assigned to four
cycles of therapy. Kaplan-Meier curves for these groups are illustrated
in Figure 2. Results of multivariate proportional hazards modeling
indicatedthatsixcyclesoftherapywasnotsuperiortofourcyclesforeither
RFS or OS after adjusting for the effects of tumor size, number of positive
nodes, hormone receptor status, and menopausal status. The observed
adjusted HR of 6:4 cycles for RFS was 1.03 (95% CI, 0.84 to 1.28; P .77)
and for OS was 1.12 (95% CI, 0.84 to 1.49; P  .44; Table 2).
Unplanned subset analyses were performed based on tumor ER
and HER2 status. There was no interaction between the number of
cycles of therapy and any of these variables, suggesting that no sub-
group benefitted from a longer period of therapy.
Although the DSMB has not released data for the comparison of
AC versus T, it has informed us that there was no interaction be-
tween treatment duration and chemotherapy regimen. The above-
referenced predictive probability calculation of .001 for eventual
superiority of six cycles versus four cycles was based on the assumption
that there was in fact no interaction.
Toxicities
Patients’ principal toxicities are listed in Table 3. As expected,
hematologic toxicity was most pronounced in the AC study arms
compared with the T arms and was slightly more common in those
patients treated with six cycles of AC. Patients receiving six cycles of
AC demonstrated 11% grade 3 and 23% grade 4 neutropenia.
Neutropenia and fever (grades 3 and 4) occurred in 6% of each of
the AC study arms. Neuropathy was most common in the pacli-
taxel arms compared with the AC arms, with grade 3 sensory
toxicity occurring in 4% of those patients treated with four cycles
of paclitaxel and 10% of those treated with six cycles. Grade 3
motor neuropathy occurred in 2% of those patients who received
four cycles of paclitaxel and in 3% of patients receiving six cycles.
Less than 1% of patients reported grade 4 neuropathy of any type.
Incidence of cardiac toxicity and AML/MDS is listed in Table 4.
Cardiac toxicity was rare in all treatment arms, though more frequent
among the patients treated with six cycles of AC. Six patients were
diagnosed with AML/MDS between 11 and 28 months after initiation
of treatment; five in the AC  6 arm and one in the AC  4 arm.
Patients were 44, 44, 45, 47, 60, and 62 years old at the time of study
enrollment. No cases of AML/MDS occurred in patients treated with T.
Causes of death are listed in Table 5. Of 1,578 patients randomly
assigned to six cycles of therapy 100 died; 60 as a result of breast
cancer–related causes. Of 1,593 patients randomly assigned to the
four-cycle arms 91 died; 55 as a result of breast cancer–related causes.
There were seven treatment-related deaths, all in the AC study arms;
five as a result of AML/MDS and two as a result of cardiac causes.
DISCUSSION
This study examined a head-to-head comparison of four cycles versus
six cycles of adjuvant chemotherapy for women with early-stage breast




RFS (n  3,160) OS (n  3,160)†
HR 95% CI P HR 95% CI P
Treatment duration, cycles 6:4 1.03 0.84 to 1.28 .77 1.12 0.84 to 1.49 .44
Tumor size, cm 2:1.5 1.16 1.09 to 1.22  .001 1.21 1.12 to 1.30  .001
No. of positive nodes 2:0 1.34 0.76 to 2.33 .31 1.77 0.88 to 3.56 .11
Hormone receptor Neg:pos 1.95 1.57 to 2.42  .001 2.73 2.04 to 3.65  .001
Menopausal status Post:pre 1.13 0.91 to 1.41 .27 1.56 1.51 to 2.12 .004
Abbreviations: HR, hazard ratio; neg, negative; OS, overall survival; pos, positive; post, postmenopausal; pre, premenopausal; RFS, relapse-free survival.
11% events.
†6% events.
Table 3. Percentage of Patients With Grade 3 or 4 Adverse Events Observed During Protocol Therapy by Treatment Arm
Adverse Event
Treatment Arm (%)
AC  4 (n  762) AC  6 (n  751) T  4 (n  769) T  6 (n  759)
Grade 3 Grade 4 Grade 3 Grade 4 Grade 3 Grade 4 Grade 3 Grade 4
Hemoglobin 2 0 6  1  1 0 1  1
Neutropenia 9 17 11 23 2 1 2 1
Neutropenia and fever 5 1 6  1  1 0 0 0
Platelets 1 1 3 1  1 0 0 0
Neuropathy
Sensory 0 0  1 0 4 0 10 0
Motor  1 0  1 0 2  1 3  1
Abbreviations: AC, doxorubicin and cyclophosphamide; T, paclitaxel.
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cancer and zero to three positive axillary nodes. We found that six
cycles of a single therapy was not superior to four cycles for either RFS
or OS for the overall patient population or in unplanned subset anal-
yses, as defined by ER or HER2 tumor status. In particular, for the
1,126 patients with estrogen-receptor–negative disease, for whom one
would expect chemotherapy effect to be most influential on survival,
there was no benefit of six cycles of therapy over four cycles.
The study was powered for 567 events but the data were released
by the DSMB after 283 events had occurred because a Bayesian meth-
odology indicated that, even if the study continued until all 567 events
occurred, the probability of concluding the superiority of six over four
cycles was very small (P  .001).
Many studies addressing adjuvant therapy in this group of
women have tested four cycles versus four cycles or six cycles versus six
cycles of different regimens. None have tested four cycles versus six
cycles of therapy of the same regimen using the identical dose per cycle
and schedule of treatment, which allows for an unconfounded result.
Although NSABP B-15 tested four cycles of AC versus six cycles of
CMF and found them to be equivalent,1 some have argued that if AC
had been given for six cycles it would have been superior to CMF.
The Breast Intergroup study INT-0102 compared CMF  6 and
CAF  6, and showed no advantage for CAF over CMF. This study
indirectly suggests that CAF  6 may be equivalent to AC  4,4
because both CAF  6 and AC  4 are equivalent to CMF (adminis-
tered with 14 days of oral C, and MF given intravenously on days 1 and
8 of a 28-day cycle). In contrast, the National Cancer Institute of
Canada MA.5 trial found cyclophosphamide, epirubicin, and fluorou-
racil (CEF)  6 to be superior to CMF  6, but this study included
a different patient mix of only premenopausal women. Further, in
the MA.5 study, women with ER-positive tumors did not receive
adjuvant hormone therapy.14 In a subsequent analysis of the data
from the MA.5 study, CEF seemed superior only in women with
HER2-positive disease who did not receive trastuzumab at the time
this trial was conducted.15
NSABP B-30 compared sequential AC-T (four plus four cycles)
versus doxorubicin-docetaxel (four cycles) versus concurrent doxo-
rubicin plus cyclophosphamide plus paclitaxel (four cycles) for
women with primary, node-positive breast cancer and found that the
sequential AC-T arm yielded better DFS and OS compared with the
4-cycle arms.16 NSABP B-30 was not a pure comparison of treatment
duration because of the differences in the three chemotherapy regi-
mens, including different agents, schedules, and doses. Notably, the
longer duration arm in NSABP B-30 was composed of two sequential
regimens. The induction of menopause is another possible con-
founder. NSABP B-30 demonstrated that premenopausal patients
with ER-positive tumors who developed amenorrhea had better sur-
vival rates than those who continued to menstruate, regardless of
which regimen they received. Forty-four percent of the patients on our
study were premenopausal at study entry and the data for induction of
amenorrhea in these patients remains incomplete. However, one
might expect longer duration therapy to induce amenorrhea more
frequently than shorter therapy and, therefore, induction of amenor-
rhea is unlikely to have influenced the results of our study because
longer therapy was not associated with better survival.
Therasse et al17 compared six cycles of CEF administered every 28
days over 6 months versus six cycles of dose-dense epirubicin/cyclo-
phosphamide given every two weeks over 3 months as neoadjuvant
therapy in women with locally advanced breast cancer. Outcomes
were similar for the two treatment arms that contained different drugs
and were given on different schedules, thus not representing a pure
duration question.
As one might expect, toxicity was more severe in the six-cycle
arms, with a greater incidence of hematologic toxicity in the AC  6
study arms than in the AC  4 arms and more neurotoxicity in the
T6 arms than in the T4 arms. Similarly, the occurrence of cardiac
toxicity was greater in the AC  6 study arm when compared with the
AC  4 arm. Although the numbers are small, five of six patients
Table 4. No. of Patients With Grade 3 or Higher Cardiotoxicity or AML/Myelodysplasia Observed After Completing Protocol Therapy by Treatment Arm
Adverse Event
Treatment Arm (No. of patients)
AC  4 (n  795) AC  6 (n  789) T  4 (n  798) T  6 (n  789)
Grade 3 Grade 4 Grade 5 Grade 3 Grade 4 Grade 5 Grade 3 Grade 4 Grade 5 Grade 3 Grade 4 Grade 5
LV systolic dysfunction 5 0 0 18 5 1 0 0 0 2 1 0
Restrictive cardiomyopathy 0 0 0 2 1 0 0 0 0 0 0 0
Cardiac, other 0 0 1 1 0 0 1 0 0 2 0 0
AML/myelodysplasia 0 0 1 0 1 4 0 0 0 0 0 0
Abbreviations: AC, doxorubicin and cyclophosphamide; AML, acute myeloid leukemia; LV, left ventricular; T, paclitaxel.
Patient died as a result of myocardial infarction.









Alive 1,502 1,478 2,980
Dead 91 100 191
Cause of death
Treatment related 2 5 7
AML 1 4 5
CHF 0 1 1
MI 1 0 1
Breast cancer related 55 60 115
Other† 20 19 39
Unknown‡ 14 16 30
NOTE. Table entries are numbers of patients.
Abbreviations: AC, doxorubicin and cyclophosphamide; AML, acute myeloid
leukemia; CHF, congestive heart failure; MI, myocardial infarction.
All treatment-related deaths occurred on the AC study arms.
†Other signifies patients’ deaths were related to neither treatment
nor disease.
‡Unknown is in addition to Other.
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developed AML/MDS in the AC  6 arm, but only one patient did so
in the AC  4 arm. The development of AML/MDS is thought to be
dependent on dose, and this finding is consistent with that hypothesis.
Our study demonstrates, in a head-to-head comparison, that for
women with relatively low-risk primary breast cancer, there is no
evidence that extending chemotherapy of AC or single-agent pacli-
taxel regimens from four to six cycles improves clinical outcome. It
should be noted that the 2  2 factorial design of this study combines
the AC and T groups in the four versus six analysis and, though there
was no interaction with type of therapy, single agent T should not be
considered a standard regimen for these patients, pending the results
of the AC versus T comparison, the results of which are not yet
available. It should also be noted that more than 90% of these patients
had node-negative disease and 77% had HER2-negative disease. Tak-
ing these issues in context, patients can be spared longer and more
toxic treatment with these regimens without fear of compromising
breast cancer outcome.
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